Molecular Partners : Corporate Presentation - June 2024
Corporate Presentation June 2024 1 Disclaimer ...
Source: marketscreener.com
Molecular Partner News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Molecular Partner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Molecular Partner Today - Breaking & Trending Today
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
MP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being preparedRadio-DARPin...
Source: marketscreener.com
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two ...
MP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being preparedRadio-DARPin Therapy (RDT): Lead
Source: eagletribune.com
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action
Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cellsResults highlight MP0533-mediated T-cell activation...
Source: marketscreener.com
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference - Molecular Partners (NASDAQ:MOLN)
Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024Progress of Radio-DARPin Therapy (RDT) platform: Improved tumor to kidney uptake
Source: benzinga.com